Type 1 Diabetes: Molecular Mechanisms, Regulation and Therapy
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Endocrinology and Metabolism".
Deadline for manuscript submissions: closed (30 April 2024) | Viewed by 131
Special Issue Editor
2. Department of Medicine, St Vincent’s Hospital, University of Melbourne, Fitzroy, Victoria 3065, Australia
Interests: immunology; T cells; autoimmune diseases
Special Issue Information
Dear Colleagues,
Type 1 diabetes is an autoimmune disease that is caused by the T-cell-mediated destruction of the pancreatic insulin-producing beta cells. The cause of type 1 diabetes is unknown, but it is believed to involve a combination of genetic and environmental factors. The underlying mechanism involves an autoimmune destruction of the insulin-producing beta cells in the pancreas.
Since the discovery of insulin, over 100 years ago, T1D has been treated using exogenous insulin injection. While insulin therapy has turned T1D from an invariably fatal disease into a life-long chronic condition, people with T1D have a reduced life expectancy and a risk of complications. For this reason, there is a great need to develop immune-based therapies that address the autoimmune pathogenesis of T1D, rather than replacing insulin.
Teplizumab, an anti-CD3 mAb, was approved by the FDA for the prevention of T1D in November 2022. Teplizumab is the first immune therapy to be approved for treating T1D and heralds a new immune therapy era in the treatment of T1D. In this Special Issue, I propose to focus on emerging immune therapies for the prevention and treatment of T1D. This will be divided into three sub-categories: antigen-specific therapies, cytokine-blockade therapies and Treg-based therapies.
This Special Issue welcomes the latest developments and research in these three areas. We invite scholars to contribute original research articles, communications and reviews on topics including, but not limited to, those listed below:
- Antigen-specific therapies;
- Cytokine-blockade therapies;
- Treg-based therapies;
- The cause of type 1 diabetes;
- Immune therapies.
Dr. Stuart Mannering
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antigen-specific therapies
- cytokine-blockade therapies
- treg-based therapies
- type 1 diabetes
- immune therapies
